🔗 Share this article

While the US proceeds with sweeping revisions to its immunization recommendations, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid vaccinations in the pandemic and has focused upon potential deaths after Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Program

Public health authorities planned to announce sweeping revisions to the pediatric vaccination calendar recently, bringing the US with Denmark’s national calendar, sources say – a substantial departure that would put the US at odds with much of the world with no evidence for benefit. The planned update has been delayed until the coming year.

In place of the top vaccines chief, Dr. Høeg is scheduled to present at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this calendar year.

Consolidating Power at the FDA

This interim role could signify a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has frequently advocated for halting certain pediatric immunization guidelines in the US so as to align more like Denmark, a nation with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – traditionally the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Questions Over Qualifications

The appointee has no obvious experience in pharmaceutical research, approval processes or leadership, which has been typical for past directors of the biologics center. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, remarked Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Former directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that former directors who ran CBER have had.”

This division has an vast workload at the FDA, she emphasized.

“Many people just pays attention on the novel medication approvals, but the generic program authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and so forth, and every single one have to be managed,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a significant leadership element to the job, which manages over 5,000 staff members. “It’s a huge management job, if you do it right,” she said.

Agency Reaction and Disputed Programs

When asked about inquiries about Høeg’s credentials and whether this selection represents more teamwork among FDA leaders on immunizations, a press secretary stated that the “inquiries stem from incorrect assumptions”.

“This background matches the duties of her position,” the official stated, citing the period Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched expedited review system, a contentious expedited medication authorization process that reportedly troubled her predecessors. “By what process are these therapies being picked for this expedited pathway? Who makes the choices?” Dr. Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed oversight of all drugs, with the exception of immunizations.”

Established History on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if problematic, track record, critics said. She released a research paper using non-validated crowd-sourced reports to determine the rate of myocarditis after Covid immunization. She advised the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the new administration encompassed changing regulations for new vaccines and halting “non-essential” immunizations, she said post-election on a podcast. At the agency, Høeg has reportedly suggested barring young men from receiving Covid vaccines.

“She’s an complete ideologue who commences with her conclusions and reverse-engineers to fit the data in a very deceptive, fraudulent fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|